AvroBio Inc

Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The firm's clinical-stage programs include Fabry, Gaucher Type 1, Hunter syndrome Gaucher Type 3, Pompe, and Cystinosis. The company was founded by Geoff Mackay, Kim Warren, Christopher Mason, and Jeffrey Medin in 2015 and is headquartered in Cambridge, MA.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.

Aclaris Therapeutics

ADC Therapeutics

Allegheny Technologies

Campbell Soup

Crane Company

Cemex SAB de CV

Exact Sciences

Tuesday's futures were fairly positive after a somewhat mixed start to the week.

Tuesday Analyst Upgrades and Downgrades: Campbell Soup, Exact Sciences, Exelixis, Spirit Airlines, Sarepta, ZTO and More

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced Geoff MacKay, president and CEO of AVROBIO, will present at the JMP Securities Life Sciences Conference at 10:30 a.m. ET on Thursday, June 17, 2021. A live webcast of the presentation can be accessed under "Events and Presentations" in the Investors & Media section of the Company's website at www.avrob

AVROBIO to Present at the JMP Securities Life Sciences Conference

BeyondSpring

Fortress Biotech

Beyond Air Inc

Let us take a look at some drug/biotech stocks that are poised to beat on first-quarter earnings.

4 Biotech Stocks Set to Outpace Q1 Earnings Estimates

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today reported financial results for the quarter ended March 31, 2021 and provided a business update. “During the first quarter, we met with the U.S. Food and Drug Administration (FDA) to discuss the regulatory path for AVR-RD-01, our investigational gene therapy for Fabry disease. We plan to engage with FDA in the secon

AVROBIO Reports First Quarter 2021 Financial Results and Provides Business Update

Los Angeles, California--(Newsfile Corp. - May 12, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of AVROBIO, Inc. ("AVROBIO" or "the Company") (NASDAQ: AVRO) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. AVROBIO issued a press release before market hours on May 3, 2021....

ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against AVROBIO, Inc. and Encourages Investors with Losses to Contact the Firm

AVROBIO (AVRO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for AVROBIO (AVRO) This Earnings Season?

LOS ANGELES, May 6, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of AVROBIO, Inc. ("AVROBIO" or "the Company") (NASDAQ: AVRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against AVROBIO, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $AVRO #AVRO--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against AVROBIO, Inc.

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against AVROBIO, Inc. and Encourages Investors with Losses to Contact the Firm

AVROBIO's competing drug Fabrazyme received full approval, resulting in a 2-year delay for AVRO.

AVROBIO: Fabrazyme's Full Approval Changes Things

LOS ANGELES--(BUSINESS WIRE)---- $AVRO #AVRO--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against AVROBIO, Inc.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against AVROBIO, Inc. and Encourages Investors with Losses to Contact the Firm

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of AVROBIO, Inc. (NASDAQ: AVRO) resulting from allegations that AVROBIO may have issued materially misleading business information to the investing public. SO WHAT: If you purchased AVROBIO securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The R

BREAKING ALERT: Rosen Law Firm Encourages AVROBIO, Inc. Investors with Losses to Inquire About Class Action Investigation – AVRO

Avrobio Inc (NASDAQ: AVRO) has provided an update on its regulatory plans for AVR-RD-01, its lentiviral gene therapy for Fabry disease, currently in FAB-GT Phase 2 trial. In March, the FDA granted full approval to Sanofi's SA (NASDAQ: SNY) Fabrazyme (agalsidase beta) after it received accelerated approval based on a surrogate endpoint of reduction of GL-3 inclusions in biopsied renal peritubular capillaries (PTCs).

Avrobio Plans Registration Trial With Kidney Biopsy Endpoint To Support Potential Full Approval Of Fabry Disease Gene Therapy

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today provided an update on its regulatory plans for AVR-RD-01, the first investigational lentiviral gene therapy for Fabry disease. This update follows a recent U.S. regulatory development for Fabry disease therapies, as well as AVROBIO's receipt of minutes from the company's Type B (End-of-Phase 1) meeting with the U.S

AVROBIO Provides Regulatory Update on Investigational AVR-RD-01 for Fabry Disease

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that two oral presentations and two posters featuring data from its pipeline of lysosomal disorder gene therapy programs will be shared at the 24th virtual Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), May 11-14, 2021. Accepted abstracts will include new data points from an in

AVROBIO to Present Clinical and Preclinical Data at the ASGCT 24th Annual Meeting

AVROBIO, Inc. (AVRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

AVROBIO, Inc. (AVRO) Upgraded to Buy: What Does It Mean for the Stock?

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today reported financial results for the fourth quarter and year ended Dec. 31, 2020 and provided a business update. “It has been a highly productive period for AVROBIO, with strong new data updates across all our clinical programs, underscoring the transformative potential of our ex vivo lentiviral gene therapies. Most

AVROBIO Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides Business Update

The European Commission has designated Orphan Drug status to Avrobio Inc's (NASDAQ: AVRO) AVR-RD-04, its gene therapy to treat cystinosis. AVR-RD-04 consists of the patient's hematopoietic stem cells, genetically modified to express cystinosin, the protein deficient in cystinosis patients.

Avrobio's Cystinosis Gene Therapy Gets Orphan Drug Status In Europe

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the European Commission (EC) has granted orphan drug designation for AVR-RD-04, the company's investigational gene therapy for the treatment of cystinosis. AVR-RD-04 consists of the patient's own hematopoietic stem cells, genetically modified to express cystinosin, the protein that is deficient in pa

AVROBIO Receives Orphan Drug Designation from the European Commission for AVR‑RD‑04, an Investigational Gene Therapy for Cystinosis

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in three upcoming virtual investor conferences. Cowen 41st Annual Health Care Conference Panel: Orphan CNS Date: Thursday, March 4, 2021 Time: 10:30 a.m. ET Barclays Global Healthcare Conference Date: Tuesday, March 9, 2021 Time: 8:35

AVROBIO to Present at Three Upcoming Investor Conferences in March

AVRO dropped after bluebird's lentiglobin trials were halted because of AML/MDS concerns. Both therapies use Lentiviral vectors, hence the concern.

Avrobio: An Update After Stock Price Drop After bluebird Trial Halt

Moderna

Moderna (NASDAQ: MRNA) shares are trading higher amid South Africa stopping distribution of the AstraZeneca COVID-19 vaccine due to ineffectiveness in treating a disease variant. Moderna is working on a competing vaccine.

Why Moderna, Avrobio, And More Are Moving Today

Avrobio Inc (NASDAQ: AVRO) has reported positive data from the ongoing Phase 2 FAB-GTi Phase 1/2 trial evaluating AVR-RD-01, an ex vivo lentiviral gene therapy for Fabry disease. 100% reduction, or complete clearance, of the toxic substrate in the kidney biopsy, was observed in the first patient dosed.

Avrobio Shares Rally On Fabry Disease Gene Therapy Encouraging Benefit In Early-Stage Study

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced a 100% reduction, or complete clearance, of toxic substrate in the kidney biopsy of the first patient dosed with the plato® gene therapy platform in the ongoing Phase 2 FAB-GTi clinical trial of AVR-RD-01, an investigational ex vivo lentiviral gene therapy for Fabry disease. Kidney substrate reduction is

AVROBIO Announces 100% Kidney Substrate Reduction at 12 Months Post-Gene Therapy in First Patient Dosed with plato® Gene Therapy Platform in Fabry Disease Phase 2 Trial

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that it will host a virtual investor event to discuss new data from AVROBIO's clinical programs in Fabry disease, cystinosis and Gaucher disease type 1 presented at the virtual 17th annual WORLDSymposium™, a scientific meeting dedicated to lysosomal disorders, Feb. 8-12, 2021. The company also will host t

AVROBIO Announces Multiple Clinical Data Presentations, Posters and Events at 17th Annual WORLDSymposium™ 2021

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced Azadeh Golipour, VP of Manufacturing Operations at AVROBIO, will present virtually at the Cowen 2021 Gene Therapy: CMC & Regulatory Summit at 11:30 a.m. ET on Friday, Jan. 29, 2021. About AVROBIO Our vision is to bring personalized gene therapy to the world. We aim to prevent, halt or reverse disease t

News for AvroBio Inc Stock (AVRO)